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The standard primary treatment for spinal cord tumours is
complete resection, but this can be difficult in patients with astro-
cytomas (Epstein and Constantini, 1995). If complete resection is
impossible, or if the tumour is inoperable, radiation therapy is
usually recommended (Lunardi et al, 1993; O’Sullivan et al,
1994). Metastatic tumours (with leptomeningeal spread) and
relapses have a poor prognosis when treated with the standard
approach, and may require other forms of treatment (Bell et al,
1988; Civitello et al, 1988; Chamberlain, 1995). In the case
of holocord tumours and cases involving young children, radio-
therapy (RT) can have very severe sequelae (spinal deformities,
growth deficits, etc.) (Deutsch, 1995; Shirato et al, 1995;
Innocenzi et al, 1996). In addition, spinal irradiation may
induce anaplastic changes (Dirks, 1994) or a second malignancy,
as reported in large series of spinal cord tumours (O’Sullivan
et al, 1994).
Chemotherapy, mainly used for malignant intramedullary
tumours in combination with radiation therapy (Allen et al, 1998),
has given conflicting results. Because responses to various
chemotherapy regimens have also been reported in children with
low-grade gliomas (Packer et al, 1988, 1993; Petronio et al, 1991;
Pons et al, 1992; Chamberlain 1995; Kalifa et al, 1995), we
decided to explore the impact of chemotherapy in the management
of primary intramedullary glial tumours whatever their grade. The
goal was to improve survival in children with poor-prognosis
tumours by the adjunction of chemotherapy, and to postpone or
reduce radiotherapy in young children. Since 1992, eight children
have been treated in the French BB SFOP protocol and are the
focus of this report.
MATERIALS AND METHODS
Eligibility
The BB SFOP protocol was initially designed for malignant
central nervous system (CNS) tumours and optic pathway gliomas
in children under 5. In the course of the study, patients with
intramedullary tumours were enrolled if they were in relapse or
had an unresectable tumour, whatever their age. Patients with a
metastatic tumour at diagnosis or at relapse were also eligible.
Patients with spinal cord ependymomas were ineligible. All the
patients had progressive tumours and measurable disease at the
start of chemotherapy. None had received radiotherapy or
chemotherapy before entry to the study.
Chemotherapy
All the patients received the same BB SFOP protocol, which is the
national protocol of the French Society of Paediatric Oncology
(SFOP) (Kalifa et al, 1995). It is a 16-month polychemotherapy
regimen that includes seven cycles of carboplatin (15 mg kg–1 or
450 mg m–2 on day (d) 1), procarbazine (4 mg kg–1 or 200 mg m–2
on d 1–7), etoposide (5 mg kg–1 or 150 mg m–2 on d 22 and 23),
cisplatin 1 mg kg–1 or 30 mg m–2 on d 22 and 23), vincristine
(0.05 mg kg–1 or 1.5 mg m–2 on d 43) and cyclophosphamide
(50 mg kg–1 or 1500 mg m–2 on d 43). For children over 3, doses
were calculated in mg m–2 per day.
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Clinical status was rated using the McCormick Scale (McCormick
et al, 1990). This functional grading system analyses motor and
sensory deficits. It includes the presence or absence of pain,
without rating it (Table 1). All patients were monitored by serial
magnetic resonance imaging (MRI). Films were reviewed centrally
by a neuroradiologist of the SFOP expert panel (DC). Responses
were assessed according to the criteria of the International Society
of Paediatric Oncology (SIOP) (Gnekow, 1995).
Histology
The slides were reviewed centrally by a neuropathologist of the
SFOP expert panel (ALT). Tumours were classified according to
the WHO classification (Kleihues et al, 1993).
RESULTS
Between May 1992 and January 1998, eight children aged from 3
months to 10 years 11 months (median 4 years 11 months) were
treated for primary intramedullary tumours with the BB SFOP
Protocol.
Demographic and histological data
The histological diagnoses are given in Table 2. Six of the eight
patients had low-grade tumours, while two had grade III tumours
(patients 1 and 8). Patients 2 and 7 did not have a second biopsy at
relapse before inclusion in the study.
Disease status before chemotherapy (Table 2)
All the tumours were progressive and three patients had metas-
tases when chemotherapy began. The extent of the disease at the
outset of chemotherapy is shown in Figure 1. Patient 1 was treated
in the protocol because of a holocord neonatal tumour immedi-
ately after biopsy, and patient 4 was treated in the protocol imme-
diately after diagnosis because he had initial metastatic disease
with multiple intramedullary lesions.
Tolerance of the chemotherapy
The first line of treatment was always surgery (biopsy in patients 1
and 4, plus a ventriculo-peritoneal shunt in patient 4; partial exci-
sion in the other six patients). Chemotherapy was started either
following surgery (six patients), or at the time of relapse (32 and
45 months later, patients 7 and 2), after insertion of an implantable
port, and was very well tolerated. Only three patients had blood or
platelet transfusions. Five patients had six documented, easily
treatable infections (Staphyloccus epidermidis septicaemia in
three, urinary tract infections in two and varicella in one). All
completed the 16-month chemotherapy regimen.
Response to the BBSFOP protocol
Table 3 shows clinical status at the start and end of chemotherapy
and at the last follow-up visit. The first symptom to disappear was
pain, usually during the first cycle of chemotherapy (i.e. three
courses). Seven patients had a clinical response at the end of
chemotherapy (improvement of at least one grade on the
McCormick functional scale), while one patient was unchanged.
The clinical response was apparent after one to eight courses
(median 3.5 courses). Four children had clinical signs of bladder
dysfunction at the start of treatment, but they resolved during
chemotherapy. At the last follow-up, none of the children had
bladder dysfunction requiring urinary catheterization, although
two of them remain paraplegic. Serial urodynamic results are not
available for all the patients.
Table 4 shows the radiological response to BB SFOP
chemotherapy. At diagnosis, all the tumours involved at least
seven spinal segments, including the tumour cyst. Figure 1 shows
the extent of the disease at start of chemotherapy. All the children
had a measurable tumour at the outset of the BB SFOP protocol.
The response to chemotherapy analyses the evolution of the
tumour present at the outset.
At the end of the 16-month polychemotherapy regimen, four
patients had a complete response (CR, patients 1, 5, 6 and 8).
Three patients had a partial response (PR, patients 3, 4 and 7) and
one had stable disease (SD, patient 2). The radiological response
did not strictly match the clinical response. Patients 3 and 4 had a
measurable residue after chemotherapy, even though they were
totally asymptomatic. In addition, patient 1, who was in CR after
chemotherapy for a holocord neonatal tumour, remains paraplegic.
Figure 2A and 2B show the radiological findings in patient 1
(holocord tumour) at the beginning and end of chemotherapy. This
child entered CR during BB SFOP chemotherapy.
Relapses after BB SFOP chemotherapy
None of the eight children had tumour progression during BB
SFOP chemotherapy. Four patients relapsed or had disease
progression, 1–15 months after the end of chemotherapy. Three
had local and metastatic relapses (patients 2, 7 and 8) and one had
only a local relapse (patient 1).
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Table 1 McCormick functional scale
Grade I
Neurologically normal; mild focal deficit not significantly affecting function of involved limb; mild spasticity or reflex abnormality; normal gait.
Grade II
Presence of sensorimotor deficit affecting function of involved limb; mild to moderate gait difficulty; severe pain or dysaesthetic syndrome impairing patient’s
quality of life; still functions and ambulates independently.
Grade III
More severe neurological deficit; requires cane/brace for ambulation, or significant bilateral upper extremity impairment; may or may not function independently.
Grade IV
Severe deficit; requires wheelchair or cane/brace with bilateral upper extremity impairment; usually not independent.
Reproduced with permission from McCormick et al (1990) J Neurosurg 72: 523–532.Second-line treatment was a monthly vincristine–carboplatin
combination in three according to the protocol of the International
Society of Paediatric Oncology (SIOP) (Perilongo, 1998), adapted
from the regimen published by Packer et al (1997). The responses
were PR in one (patient 1), PD in one (patient 7) and unevaluable in
one (patient 8, who died in a car accident). Patient 1 was operated
on for a small spinal residue after 1 year of treatment with the
vincristine–carboplatin combination. Histological analysis showed
only mature glial cells. This child is alive and disease-free 1.5 years
after the end of treatment.
Patient 7 had a partial response to third-line chemotherapy
consisting of low-dose oral etoposide (Chamberlain, 1995) and
was subsequently irradiated (35 Gy) to the whole CNS with a
further improvement. He was alive and still had disease 3 months
after the end of radiotherapy.
Patient 2 was irradiated at 35 Gy to the whole CNS as second-
line treatment at the time of relapse. Craniospinal irradiation
yielded a major clinical improvement that persisted after 12
months of follow-up.
Three of the four patients who relapsed after the BB SFOP
protocol were still alive, 59, 63 and 71 months after initial
diagnosis.
Survival
In August 1998, the median follow-up was 4.8 years (1.8–5.8
years) after first treatment, and 3.8 years (1.8–5.3 years) after the
beginning of chemotherapy. Seven patients are alive, while the last
died in a car accident. The overall survival rate is 87.5% and the
event-free survival rate at 2 and 4 years is 50%. At the last follow-
up visit five patients (patients 2, 3, 4, 5 and 6) were ambulatory
(3–5.5 years after beginning of chemotherapy). Two patients are
paraplegic; one was quadriplegic at diagnosis and one became para-
plegic after a second relapse. Four patients are in continuous remis-
sion without the use of radiation therapy (patients 1, 4, 5 and 6).
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Table 2 Characteristics of the patients
Patient Age Surgery Histology Outcome before BB SFOP
1 3 months Biopsy AOA NA (holocord tumour)
2 11 years Partial OA Local and metastatic relapse at 45 months
3 12 months Partial ANOS Growing residue at 2 months
4 4.5 years Biopsy + VPS OA NA (initial metastases)
5 18 months Partial JPA Growing residue at 2 months
6 3 years Partial JPA Growing residue at 2 months
7 9.5 years Partial OA Local and metastatic relapse at 32 months
8 6 years Partial AA Growing residue at 2 months
VPS=ventriculoperitoneal shunt; AOA=anaplastic oligo-astrocytoma; OA=oligoastrocytoma; ANOS=astrocytoma not otherwise
specified; JPA=juvenile pilocytic astrocytoma; AA=anaplastic astrocytoma; NA=not available because the chemotherapy was initiated
shortly after diagnosis because of the status of the disease.
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Figure 1 Disease extension at the beginning of chemotherapy. The
extension of the disease along the spinal cord is given, and includes the cyst.
The order of the bars from left to right follow the order of the patients in the
study (patient 1 on the left). The asterisks indicate patients with
leptomeningeal spread
Table 3 Clinical outcome during and after chemotherapy according to the
McCormick scale
Patient Age at diagnosis Start End Last visit Follow-up
1 3 months IV III III 5.5 years
2 11 years III III II* 3 years
3 1 year III I I 5.5 years
4 4.5 years III II I 4 years
5 1.5 years IV I I 3.5 years
6 3 years III I I 3 years
7 9.5 years III I III* 3 years
8 6 years IV I NE* DWD
NE = not evaluable because of death from other causes. * = relapse after
completion of BBSFOP protocol. DWD = death with disease. Follow-up
duration is given from beginning of chemotherapy.DISCUSSION
Paediatric intramedullary spinal cord tumours are rare, and so are
data on treatment strategies and outcomes. Surgery alone is
usually the treatment of choice for low-grade tumours, provided
that subtotal resection is possible (Guidetti et al, 1981; Epstein and
Epstein, 1982; Lunardi et al, 1993; Epstein and Constantini, 1995;
Goh et al, 1997; Mottl and Koutecky, 1997). Adjuvant treatment
with irradiation and/or chemotherapy are usually reserved for
high-grade or metastatic tumours, as their prognosis with surgery
alone is poor (Cohen et al, 1989; Bouffet et al, 1995; Goh et al,
1997; Allen et al, 1998). However, adjuvant treatment may be
considered even for low-grade tumours after incomplete surgery
or metastatic or local relapses, and it may be the first line of treat-
ment for unresectable tumours. The place of chemotherapy in
these situations has not previously been explored. We report the
first series of patients treated with a single chemotherapy protocol
(BB SFOP). Our results show that this treatment is safe and very
effective, in clinical and radiological terms, in patients whose
prognosis is otherwise poor.
There are only a few case reports of this treatment modality in
intramedullary astrocytoma. Bouffet et al (1997) reported the case
of a 30-year-old woman with a grade II spinal cord astrocytoma
treated first with carboplatin, who entered full neurological and
radiological remission. The result was promising despite the short
follow-up. However, using the same chemotherapy, Foreman et al
(1998) reported a treatment failure in an 8-year-old child treated at
time of relapse of a low-grade glioma. In a report from Bristol
(Lowis et al, 1998), responses to chemotherapy were observed in a
19-month-old child with anaplastic astrocytoma of the cervical
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Table 4 Radiological response during and after chemotherapy
Patient Histology Tumour Response at end of BBSFOP Status of disease at follow-up
1 AOA Holocord, not operated CR CR2 at 5.5 yearsa
2 OA Local and metastatic relapse SD PRb at 3 years
3 ANOS Residue PR SD at 5.5 years
4 OA Initial metastases, not operated PR VGPR at 4 years
5 JPA Residue CR CCR at 3.5 years
6 JPA Residue CR CCR at 3 years
7 OA Local and metastatic relapse PR SDc at 3 years
8 AA Residue CR DWDd at 32 months
The response to BB SFOP protocol is analysed by comparing the MRI performed just before chemotherapy and the one performed at the end of chemotherapy.
Changes in the contrast enhancement of the lesion without modification of the size were not considered as a response. If there is discrepancy between the
evolution of multiple lesions, only the worst response is considered. The status of the disease is analysed by comparing the MRI at the end of the chemotherapy
and the last available radiological films. aOne year after the end of BB SFOP chemotherapy, this patient had a local relapse that showed a partial response to a
second-line chemotherapy. A complete surgical resection of the residue was performed and pathological analysis showed only mature glial cells. bThe patient 2
was irradiated shortly after the end of chemotherapy with clinical signs of tumour progression. cThe patient 7 relapsed again 22 months after diagnosis of his
first relapse (i.e. after the start of BB SFOP chemotherapy), exhibited a partial response to a second-line chemotherapy (oral etoposide) of 6 months duration
and was subsequently irradiated. dThe patient 8 had a metastatic relapse 2.5 years after the diagnosis, received salvage treatment with second-line
chemotherapy but died in a car accident 32 months from diagnosis while on treatment.
Figure 2 Response to BB SFOP chemotherapy in a 3-month-old girl with a holocord tumour. This 3-month-old baby presented with quadriplegia, the Claude
Bernard Horner sign and stiff neck. MRI showed a holocord tumour from C2 to L5 with no evidence of leptomeningeal spread (A). After the first cycle, her
clinical condition improved dramatically, in parallel with radiological signs. At the end of BB SFOP chemotherapy she remained paraplegic without significant
bladder dysfunction, and MRI showed a complete response (B)
A Bspinal cord, and in a 4-year-old child with a recurrent low-grade
astrocytoma. Again, follow-up was short in both cases.
Unpublished data on the use of vincristine–carboplatin combi-
nation in intramedullary tumours are available from the Children’s
Cancer Group and the SIOP consortium for low-grade tumours.
Fort and Packer reported one CR and one PR in five patients at the
Paediatric Neuro-Oncology Symposium in Rome (Fort et al,
1998). In the SIOP protocol, two of four assessable patients with
low-grade spinal gliomas responded to this combination
(Perilongo 1998).
At the outset of chemotherapy, three of our patients had
leptomeningeal metastases; this is a rare event in benign CNS
tumours in children (Hardison et al, 1987; Bell et al, 1988; Civitello
et al, 1988), being more frequent with intramedullary tumours and
malignant tumours (Chamberlain, 1995). Chemotherapy induced
two PR and one SD in our three children with leptomeningeal
dissemination. One of the children with PR (patient 4) is progres-
sion-free 4 years after diagnosis. The other child with PR (patient 7)
and the child with SD (patient 2) subsequently relapsed, were irra-
diated and remain progression-free (3 months and 1 year after
completion of RT respectively). Survival after leptomeningeal
relapses of intramedullary tumours is poor. One of the three chil-
dren reported by Bell et al (1988) was treated with systemic
chemotherapy and was alive 10 months after relapsing, with stable
residual disease. All the patients reported by Chamberlain in a
review of the paediatric literature in 1995 (Chamberlain, 1995) died
within 6 months of the onset of leptomeningeal dissemination.
They had various primary tumours and were treated with RT and
intrathecal chemotherapy. Two of the three patients reported by
Civitello et al (1988) were alive 9 and 44 months after relapsing.
They both received chemotherapy, and one also had craniospinal
radiotherapy (csRT). The two children reported by Hardison et al
(1987) were treated with both chemotherapy and csRT and died 10
and 11 months later. Although it is clear that dissemination is asso-
ciated with very poor outcome in patients with glial tumours, it is
not clear whether early and secondary dissemination of glial
tumours have the same prognostic impact.
Even in our two patients with high-grade tumours we obtained
lengthy complete remissions; this is quite unusual according to the
literature on malignant astrocytomas, which are characterized by
rapid neurological deterioration and death (Cohen et al, 1989;
Allen et al, 1998).
The most interesting result of chemotherapy was a marked
improvement in functional status: our results compare favourably
with those of surgery in other paediatric (Epstein and Epstein,
1982; Reimer and Onofrio, 1985; Hardison et al, 1987; Constantini
et al, 1996; Innocenzi et al, 1996; Goh et al, 1997) and adult series
(Guidetti et al, 1981; Cooper, 1989). In the paediatric literature,
clinical improvement after surgery is observed in 0.7–73% of cases
(Epstein and Constantini, 1995; Goh et al, 1997). The neurosur-
geons of New York University obtained improvements in 18.5% of
cases after surgery of intramedullary spinal cord tumours in chil-
dren under 3 years of age (Constantini et al, 1996). In this latter
series, 69% of patients were ambulatory with 76 months of follow-
up. Functional status improved after surgery in only 2/29 children
with astrocytomas reported by Innocenzi and Raimondi, and wors-
ened in four cases (Innocenzi et al, 1996). In an adult series with
long-term results (mean 38 months) for 51 intrameduallary spinal
cord tumours after surgery, 29% patients were improved, 80% were
ambulatory and 20% were neurologically intact (Cooper et al,
1989). Guidetti et al (1981) report their treatment results for 53
adults with intramedullary astrocytomas; only 10% were improved
after surgical treatment (12–324 months follow-up). In our study,
functional status improved even in the patient with a holocord
tumour. In addition, side-effects were minor compared with those
described after RT (O’Sullivan et al, 1994; Deutsch, 1995; Shirato
et al, 1995) or extensive surgery (Guidetti et al, 1981; Reimer and
Onofrio, 1985; Innocenzi et al, 1996).
Survival in this small series was good. None of the patients died
of their disease, and half of them had no relapse after a median
follow-up of 5 years from diagnosis and 4 years from the outset of
chemotherapy. In the main paediatric series of intramedullary
tumours (Epstein and Epstein, 1982; Reimer and Onofrio, 1985;
Hardison et al, 1987; Lunardi et al, 1993; Constantini et al, 1996;
Innocenzi et al, 1996; Goh et al, 1997; Mottl et al, 1997), treatment
consisted of surgery alone or combined with radiotherapy. With a
follow-up of 5 years, the reported overall survival rate was
between 39 and 96%, and the event-free survival rate was between
14 and 77%.
In conclusion, chemotherapy should be considered for children
with a poor prognosis due to relapse or metastasis of an
intramedullary tumour. Chemotherapy could even be the first line
of treatment for metastatic and unresectable tumours (e.g. holo-
cord tumours) and replace extensive irradiation. Moreover, when
adjuvant treatment is indicated after incomplete resection,
chemotherapy may delay or avoid the use of irradiation, which can
have severe sequelae in young children. Because these tumours are
rare, large cooperative studies will be necessary to further explore
the value of chemotherapy in intramedullary glial tumours.
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